Nstemi symptoms within 48 hours prior to study entry Elevated troponin


Download 445 b.
Sana14.08.2018
Hajmi445 b.









































Inclusion



































In NSTEMI patients managed invasively within 48 hours of randomization, pre-treatment with prasugrel does not reduce major ischemic events up to 30 days and increases major bleeding complications.

  • In NSTEMI patients managed invasively within 48 hours of randomization, pre-treatment with prasugrel does not reduce major ischemic events up to 30 days and increases major bleeding complications.

  • The efficacy and safety results are consistent among patients undergoing PCI

  • No subgroup appears to have a favorable risk/benefit ratio with pre-treatment.





in intermediate risk NSTEMI patients

  • in intermediate risk NSTEMI patients

  • early invasively managed (median 4.3 hrs post randomisation)

  • pre-treatment with 30 mg of prasugrel (+ 30 mg at the time of PCI) does not reduce major ischemic events up to 30 days but increases major bleeding complications.

  • ( The efficacy and safety results are consistent among patients undergoing PCI. No subgroup appears to have a favorable risk/benefit ratio with pre-treatment)

  • Drug failure or strategy failure ?






































































Do'stlaringiz bilan baham:


Ma'lumotlar bazasi mualliflik huquqi bilan himoyalangan ©fayllar.org 2017
ma'muriyatiga murojaat qiling